BIPHETAMINE 12.5
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Sep 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BIPHETAMINE 12.5 is a brand-name oral extended-release capsule approved in 1955, indicating it is a legacy amphetamine-based product of unknown mechanism and indication details. The product is currently approaching loss of exclusivity, suggesting it is a long-established treatment with limited patent protection remaining.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on margin defense and niche positioning rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BIPHETAMINE 12.5 represents a legacy product portfolio opportunity with limited growth upside; career value centers on lifecycle management, cost containment, and transition planning. Roles on this product prioritize operational efficiency and compliance over market expansion.
Brand ManagerField Sales
Worked on BIPHETAMINE 12.5 at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.